Cargando…
THU609 Timeline For Undetectable Mitotane Plasma Levels In Adrenocortical Carcinoma Patients After Stopping Treatment
Disclosure: N. Younes: None. P. Hétu: None. A. Lacroix: None. I. Bourdeau: None. Background: Mitotane (o,p’DDD) is an adrenolytic steroidogenesis inhibitor recommended in the treatment of adrenocortical carcinoma (ACC) with a high risk of recurrence. Mitotane has a long plasma elimination half-life,...
Autores principales: | Younes, Nada, Hétu, Pierre-Olivier, Lacroix, André, Bourdeau, Isabelle |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10554058/ http://dx.doi.org/10.1210/jendso/bvad114.139 |
Ejemplares similares
-
THU617 Prolonged Exposure To Target Mitotane Concentrations Is Associated With Better Recurrence-free Survival In Patients With Adrenocortical Carcinoma On Adjuvant Treatment
por: Puglisi, Soraya, et al.
Publicado: (2023) -
FRI199 Severe Hypertriglyceridemia And Acute Pancreatitis In A Patient With Adrenocortical Carcinoma (ACC) Taking Mitotane
por: Cortez, Briana Noel, et al.
Publicado: (2023) -
THU616 Analysis Of Germline Mutations In Patients With Sporadic Adrenocortical Carcinoma
por: Terzolo, Massimo, et al.
Publicado: (2023) -
THU620 Metastatic Adrenocortical Carcinoma Arising From A Testicular Rest Tumor
por: Chozet, Luis Edmundo, et al.
Publicado: (2023) -
SAT313 Therapeutic Dosing Of Steroids In Patients On Mitotane
por: Pham, Christopher, et al.
Publicado: (2023)